Morningstar

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the ...
La Grande Observer

Alamar Biosciences launches the NULISAqpcr™ Custom Assay Development Kit to advance the development of novel biomarker assays for clinical research

FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...
Healio

Partnership to advance customized biomarker assays for range of neurological conditions

Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...
MarketWatch

Alamar Biosciences Launches NULISAseq(TM) Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research

The MarketWatch News Department was not involved in the creation of this content. New panel expands coverage for Alzheimer's and Parkinson's diseases including 15 new biomarkers developed with support ...
MarketWatch

Alamar Biosciences Launches NULISAqpcr(TM) BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

The MarketWatch News Department was not involved in the creation of this content. New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay ...
Business Wire

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

SAN DIEGO--(BUSINESS WIRE)--Sapient, a leader in multi-omics discovery, has partnered with Alamar Biosciences, a pioneer in ultra-sensitive and highly multiplexed immunoassay technologies, to extend ...
WRIC

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

FREMONT, Calif., Oct. 9, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ ...